Table 3.
General linear model for MME outcome with and without adjusting for fentanyl use
| Outcome | Predictor | Comparison/reference | Estimate (95% CI) | p value |
|---|---|---|---|---|
| Ln MME | Age | – | − 0.029 (− 0.035, − 0.024) | < 0.0001 |
| Psychotropicsa | Yes/no | 0.40 (0.22, 0.57) | < 0.0001 | |
| BMI | – | 0.021 (0.0095, 0.032) | 0.0003 | |
| Sex | Female/male | − 0.22 (− 0.36, − 0.07) | 0.0033 | |
| Treatment | MMA/opioid-based | 0.22 (0.089, 0.34) | 0.0009 | |
| Ln MME (Fentanyl Adjusted) | Age | – | − 0.031 (− 0.036, − 0.027) | < 0.0001 |
| Sex | Female/male | − 0.27 (− 0.38, − 0.16) | < 0.0001 | |
| Psychotropics a | Yes/no | 0.23 (0.095, 0.36) | 0.0007 | |
| BMI | – | 0.013 (0.095, 0.36) | 0.0031 |
MME Morphine Milligram Equivalents, MMA Multimodal analgesia pathway group, Ln Natural log, CI Confidence Interval
aPsychotropics: selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor, tricyclic antidepressants, or benzodiazepines